Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
26 hedge funds and large institutions have $39.5M invested in Allena Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 15 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
26% less funds holding
Funds holding: 35 → 26 (-9)
34% less capital invested
Capital invested by funds: $59.8M → $39.5M (-$20.3M)
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.48M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$802K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$801K |
| 4 |
Renaissance Technologies
New York
|
+$379K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$321K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.94M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.92M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.35M |
| 4 |
PA
Perceptive Advisors
New York
|
-$521K |
| 5 |
JP Morgan Chase
New York
|
-$223K |
ALNA Hedge Fund Activity: Q4 2019 in Review
26 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q4 2019, worth a combined $39.5M — down 34% from $59.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ALNA and 6 opened new positions — a net loss of 9 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $1.48M. The largest seller was Morgan Stanley, cutting an estimated $2.94M.
- 26 institutional investors held Allena Pharmaceuticals (ALNA) as of Q4 2019, down from 35 in Q3 2019.
- Funds reported $39.5M of Allena Pharmaceuticals stock for Q4 2019, down 34% quarter-over-quarter.
- 6 funds opened new Allena Pharmaceuticals positions in Q4 2019 and 15 closed out, a net change of -9 holders.
- The largest Allena Pharmaceuticals buyer in Q4 2019 was Deutsche Bank, an estimated $1.48M added.
- The largest Allena Pharmaceuticals seller in Q4 2019 was Morgan Stanley, an estimated $2.94M sold.
Based on aggregated 13F filings for Q4 2019.